BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 26096139)

  • 1. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer.
    Chi KN; Spratlin J; Kollmannsberger C; North S; Pankras C; Gonzalez M; Bernard A; Stieltjes H; Peng L; Jiao J; Acharya M; Kheoh T; Griffin TW; Yu MK; Chien C; Tran NP
    J Clin Pharmacol; 2015 Dec; 55(12):1406-14. PubMed ID: 26096139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer.
    Stuyckens K; Saad F; Xu XS; Ryan CJ; Smith MR; Griffin TW; Yu MK; Vermeulen A; Nandy P; Poggesi I
    Clin Pharmacokinet; 2014 Dec; 53(12):1149-60. PubMed ID: 25204404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study.
    Stein CA; Levin R; Given R; Higano CS; Nemeth P; Bosch B; Chapas-Reed J; Dreicer R
    Urol Oncol; 2018 Feb; 36(2):81.e9-81.e16. PubMed ID: 29150328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study.
    Posadas EM; Chi KN; de Wit R; de Jonge MJA; Attard G; Friedlander TW; Yu MK; Hellemans P; Chien C; Abrams C; Jiao JJ; Saad F
    Clin Cancer Res; 2020 Jul; 26(14):3517-3524. PubMed ID: 32366670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer.
    Chi KN; Tolcher A; Lee P; Rosen PJ; Kollmannsberger CK; Papadopoulos KP; Patnaik A; Molina A; Jiao J; Pankras C; Kaiser B; Bernard A; Tran N; Acharya M
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):237-44. PubMed ID: 23064959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics.
    Lubberman FJE; Benoist GE; Gerritsen W; Burger DM; Mehra N; Hamberg P; van Oort I; van Erp NP
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1179-1185. PubMed ID: 31515667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
    Smith MR; Rathkopf DE; Mulders PF; Carles J; Van Poppel H; Li J; Kheoh T; Griffin TW; Molina A; Ryan CJ
    J Urol; 2015 Nov; 194(5):1277-84. PubMed ID: 26151676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing.
    Inoue K; Shishido A; Vaccaro N; Jiao J; Stieltjes H; Bernard A; Yu M; Chien C
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):49-58. PubMed ID: 25344090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate.
    Hussaini A; Olszanski AJ; Stein CA; Bosch B; Nemeth P
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):479-486. PubMed ID: 28695267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation.
    Yu A; Hazra A; Jiao JJ; Hellemans P; Mitselos A; Tian H; Ruixo JJP; Haddish-Berhane N; Ouellet D; Russu A
    Clin Pharmacokinet; 2024 Apr; 63(4):511-527. PubMed ID: 38436924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies.
    Goldwater R; Hussaini A; Bosch B; Nemeth P
    Clin Pharmacokinet; 2017 Jul; 56(7):803-813. PubMed ID: 28425029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
    Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
    Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
    Fizazi K; Chi KN; de Bono JS; Gomella LG; Miller K; Rathkopf DE; Ryan CJ; Scher HI; Shore ND; De Porre P; Londhe A; McGowan T; Pelhivanov N; Charnas R; Todd MB; Montgomery B
    Eur Urol; 2016 Sep; 70(3):438-44. PubMed ID: 26965562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, phase I, 3-way crossover study to examine the effects of food on the pharmacokinetics of single doses of 400 mg posaconazole oral suspension in healthy male Taiwanese subjects.
    Lin TY; Yang MH; Chang FY
    Ther Drug Monit; 2013 Apr; 35(2):223-7. PubMed ID: 23503449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Xu XS; Ryan CJ; Stuyckens K; Smith MR; Saad F; Griffin TW; Park YC; Yu MK; De Porre P; Vermeulen A; Poggesi I; Nandy P
    Clin Pharmacokinet; 2017 Jan; 56(1):55-63. PubMed ID: 27324190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer.
    Arasaratnam M; Crumbaker M; Bhatnagar A; McKay MJ; Molloy MP; Gurney H
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):139-146. PubMed ID: 31081533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
    Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
    Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 1, Randomized, Single-Dose Crossover Pharmacokinetic Study to Investigate the Effect of Food Intake on Absorption of Orteronel (TAK-700) in Healthy Male Subjects.
    Suri A; Pham T; MacLean DB
    Clin Pharmacol Drug Dev; 2016 May; 5(3):188-95. PubMed ID: 27163497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients.
    Blanchet B; Carton E; Alyamani M; Golmard L; Huillard O; Thomas-Scheomann A; Vidal M; Goldwasser F; Sharifi N; Alexandre J
    Pharmacol Res; 2018 Oct; 136():56-61. PubMed ID: 30142421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.